209 related articles for article (PubMed ID: 29530101)
61. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study.
Mezheyeuski A; Ponten F; Edqvist PH; Sundström M; Thunberg U; Qvortrup C; Pfeiffer P; Sorbye H; Glimelius B; Dragomir A
Acta Oncol; 2020 Mar; 59(3):284-290. PubMed ID: 31769323
[No Abstract] [Full Text] [Related]
62. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
63. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
64. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
65. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
Yoshino T; Portnoy DC; Obermannová R; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; García-Alfonso P; Cohn AL; Van Cutsem E; Yamazaki K; Lonardi S; Muro K; Kim TW; Yamaguchi K; Grothey A; O'Connor J; Taieb J; Wijayawardana SR; Hozak RR; Nasroulah F; Tabernero J
Ann Oncol; 2019 Jan; 30(1):124-131. PubMed ID: 30339194
[TBL] [Abstract][Full Text] [Related]
66. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
67. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
[TBL] [Abstract][Full Text] [Related]
68. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
Kruger S; Heinemann V; Ross C; Diehl F; Nagel D; Ormanns S; Liebmann S; Prinz-Bravin I; Westphalen CB; Haas M; Jung A; Kirchner T; von Bergwelt-Baildon M; Boeck S; Holdenrieder S
Ann Oncol; 2018 Dec; 29(12):2348-2355. PubMed ID: 30346475
[TBL] [Abstract][Full Text] [Related]
69. Optimization of
Santos C; Azuara D; Garcia-Carbonero R; Alfonso PG; Carrato A; Elez ME; Gomez A; Losa F; Montagut C; Massuti B; Navarro V; Varela M; Lopez-Doriga A; Moreno V; Valladares M; Manzano JL; Vieitez JM; Aranda E; Sanjuan X; Tabernero J; Capella G; Salazar R
Mol Cancer Ther; 2017 Sep; 16(9):1999-2007. PubMed ID: 28626084
[TBL] [Abstract][Full Text] [Related]
70. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
71. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
Goey KKH; Elias SG; van Tinteren H; Laclé MM; Willems SM; Offerhaus GJA; de Leng WWJ; Strengman E; Ten Tije AJ; Creemers GM; van der Velden A; de Jongh FE; Erdkamp FLG; Tanis BC; Punt CJA; Koopman M
Ann Oncol; 2017 Sep; 28(9):2128-2134. PubMed ID: 28911067
[TBL] [Abstract][Full Text] [Related]
72. Liquid biopsy for
Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM
Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810
[No Abstract] [Full Text] [Related]
73. Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer.
Klein-Scory S; Wahner I; Maslova M; Al-Sewaidi Y; Pohl M; Mika T; Ladigan S; Schroers R; Baraniskin A
Front Oncol; 2020; 10():1115. PubMed ID: 32766143
[TBL] [Abstract][Full Text] [Related]
74. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
[TBL] [Abstract][Full Text] [Related]
75. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
76. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
77. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
78. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
79. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
[TBL] [Abstract][Full Text] [Related]
80. Clinical Validation of Plasma-Based Genotyping for
Aoki Y; Nakamura Y; Denda T; Ohta T; Esaki T; Shiozawa M; Yamaguchi K; Yamazaki K; Sunakawa Y; Kato T; Okano N; Taniguchi H; Sato T; Oki E; Nishina T; Komatsu Y; Matsuhashi N; Goto M; Yasui H; Ohtsubo K; Moriwaki T; Takahashi N; Horita Y; Boku S; Wakabayashi M; Ikeno T; Mitani R; Yuasa M; Yoshino T
JCO Precis Oncol; 2023 Jun; 7():e2200688. PubMed ID: 37343204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
